Regnum Signs Assignment and Assumption Agreement w
Post# of 154032
(Total Views: 932)
Posted On: 01/10/2022 9:03:19 AM
Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV
In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, SevenScore will receive 4,094,023 shares of Regnum Corp.
PR Newswire
NEW YORK, Jan. 10, 2022
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Regnum Corp. (OTCMKT: RGMP) ("Regnum"
, CytoDyn Inc. (OTC.QB: CYDY) ("CytoDyn", and SevenScore Pharmaceuticals, LLC ("SevenScore", today announced the assignment of the Commercialization and License Agreement ("CLA" and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV from SevenScore to Regnum. The CLA was signed between Vyera Pharmaceuticals, LLC ("Vyera" and CytoDyn on December 17, 2019 and assigned to SevenScore on October 29, 2020.
Under the terms of the CLA, Regnum has been granted an exclusive license to market and distribute leronlimab in the U.S. for the treatment of HIV and CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications. In exchange for such exclusive license, Regnum has agreed to pay regulatory and sales-based milestone payments, as well as a royalty of 50 percent on net sales.
"CytoDyn expects to file the BLA for leronlimab for the treatment of HIV with FDA in the first quarter of 2022," stated Dr. Nader Pourhassan, President and CEO of CytoDyn. "We look forward to working closely with the Regnum team to launch leronlimab and bring this important new treatment option to patients infected with HIV."
Anne Kirby, Chief Executive Officer of Regnum Corp., noted: "This is an important step towards Regnum's evolution into a fully integrated biopharmaceutical company. Our partnership with CytoDyn aligns with our commitment to bringing novel therapies to patient populations in need of new treatment options or refined care plans."
In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, SevenScore will receive 4,094,023 shares of Regnum Corp.
PR Newswire
NEW YORK, Jan. 10, 2022
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Regnum Corp. (OTCMKT: RGMP) ("Regnum"
, CytoDyn Inc. (OTC.QB: CYDY) ("CytoDyn", and SevenScore Pharmaceuticals, LLC ("SevenScore", today announced the assignment of the Commercialization and License Agreement ("CLA" and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV from SevenScore to Regnum. The CLA was signed between Vyera Pharmaceuticals, LLC ("Vyera" and CytoDyn on December 17, 2019 and assigned to SevenScore on October 29, 2020. Under the terms of the CLA, Regnum has been granted an exclusive license to market and distribute leronlimab in the U.S. for the treatment of HIV and CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications. In exchange for such exclusive license, Regnum has agreed to pay regulatory and sales-based milestone payments, as well as a royalty of 50 percent on net sales.
"CytoDyn expects to file the BLA for leronlimab for the treatment of HIV with FDA in the first quarter of 2022," stated Dr. Nader Pourhassan, President and CEO of CytoDyn. "We look forward to working closely with the Regnum team to launch leronlimab and bring this important new treatment option to patients infected with HIV."
Anne Kirby, Chief Executive Officer of Regnum Corp., noted: "This is an important step towards Regnum's evolution into a fully integrated biopharmaceutical company. Our partnership with CytoDyn aligns with our commitment to bringing novel therapies to patient populations in need of new treatment options or refined care plans."
(7)
(0)